Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. Regeneron (REGN) Draws Higher Target From TD Cowen The same day, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted its expanding immunology portfolio and pipeline, announcing that 36 abstracts across its immunology and inflammation portfolio and ...